Myriad Genetics Inc Cash Flow Conversion Efficiency
Myriad Genetics Inc cash flow conversion efficiency. Based on the latest financial reports, Myriad Genetics Inc (MYGN) has a cash flow conversion efficiency ratio of -0.027x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-8.30 Million) by net assets ($303.90 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Myriad Genetics Inc (1995–2025)
Cash flow conversion efficiency of Myriad Genetics Inc from 1995 to 2025. This chart illustrates how Myriad Genetics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View MYGN share price today for real-time trading data and today's change.
Myriad Genetics Inc Cash Flow Conversion Ratio Explained
Myriad Genetics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Myriad Genetics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Myriad Genetics Inc ranked by their cash flow conversion efficiency. Also see MYGN company net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
PI Advanced Materials Co. Ltd
KQ:178920
|
0.051x |
|
CJ Corp 4P Pref
KO:00104K
|
0.102x |
|
Sophia Genetics SA
NASDAQ:SOPH
|
-0.145x |
|
Pinlive Foods Co Ltd
SHE:300892
|
0.009x |
|
Experian PLC
LSE:EXPN
|
0.251x |
|
Virgin Galactic Holdings Inc
NYSE:SPCE
|
-0.239x |
|
Ideal Group S.A
AT:INTEK
|
-0.010x |
|
Beijing InHand Networks Technology Co Ltd
SHG:688080
|
0.071x |
Annual Cash Flow Conversion Efficiency for Myriad Genetics Inc (1995–2025)
The table below shows the annual cash flow conversion efficiency of Myriad Genetics Inc from 1995 to 2025. Review MYGN FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $368.00 Million | $1.80 Million | 0.005x | +139.42% |
| 2024-12-31 | $701.10 Million | $-8.70 Million | -0.012x | +91.24% |
| 2023-12-31 | $783.20 Million | $-110.90 Million | -0.142x | -17.99% |
| 2022-12-31 | $885.80 Million | $-106.30 Million | -0.120x | -724.41% |
| 2021-12-31 | $967.80 Million | $18.60 Million | 0.019x | -79.77% |
| 2020-12-31 | $881.00 Million | $83.70 Million | 0.095x | +23.60% |
| 2019-12-31 | $1.09 Billion | $83.70 Million | 0.077x | -35.93% |
| 2018-12-31 | $966.10 Million | $115.90 Million | 0.120x | -13.24% |
| 2017-12-31 | $768.00 Million | $106.20 Million | 0.138x | -37.79% |
| 2016-12-31 | $748.10 Million | $166.30 Million | 0.222x | +4.76% |
| 2015-12-31 | $662.10 Million | $140.50 Million | 0.212x | -19.78% |
| 2014-12-31 | $719.00 Million | $190.20 Million | 0.265x | +10.83% |
| 2013-12-31 | $728.59 Million | $173.90 Million | 0.239x | +6.99% |
| 2012-12-31 | $635.66 Million | $141.80 Million | 0.223x | -3.35% |
| 2011-12-31 | $566.79 Million | $130.83 Million | 0.231x | -17.01% |
| 2010-12-31 | $557.58 Million | $155.09 Million | 0.278x | +43.71% |
| 2009-12-31 | $434.22 Million | $84.04 Million | 0.194x | -20.58% |
| 2008-12-31 | $425.65 Million | $103.74 Million | 0.244x | +420.88% |
| 2007-12-31 | $340.36 Million | $-25.85 Million | -0.076x | +32.31% |
| 2006-12-31 | $249.78 Million | $-28.03 Million | -0.112x | +34.67% |
| 2005-12-31 | $135.67 Million | $-23.30 Million | -0.172x | +3.62% |
| 2004-12-31 | $173.28 Million | $-30.88 Million | -0.178x | +37.40% |
| 2003-12-31 | $163.49 Million | $-46.54 Million | -0.285x | -124.90% |
| 2002-12-31 | $128.87 Million | $-16.31 Million | -0.127x | -367.92% |
| 2001-12-31 | $139.56 Million | $-3.78 Million | -0.027x | -112.25% |
| 2000-12-31 | $77.71 Million | $17.16 Million | 0.221x | +175.51% |
| 1999-12-31 | $48.20 Million | $-14.10 Million | -0.293x | -140.29% |
| 1998-12-31 | $57.50 Million | $-7.00 Million | -0.122x | -22.11% |
| 1997-12-31 | $66.20 Million | $-6.60 Million | -0.100x | -599.91% |
| 1995-12-31 | $70.20 Million | $1.40 Million | 0.020x | -- |
About Myriad Genetics Inc
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovar… Read more